Physician profile
Dylan B Devries
NPI 1770760365
$1,719.49
in general payments reported to CMS, 2019-2025
17 companies · $46.36 in 2025
The $46.36 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $446 · 2024: $1,227 · 2025: $46.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $310.00 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $302.44 | 2023-2025 | |
| Lilly USA, LLC | $280.64 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $188.56 | 2023-2024 | Airsupra, Farxiga |
| Pfizer INC. | $128.44 | 2023-2024 | |
| Glaxosmithkline, LLC. | $116.72 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $89.86 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.05 | 2023-2024 | Jardiance |
| Amgen INC. | $44.94 | 2023-2024 | Repatha, Prolia, Evenity |
| Corcept Therapeutics | $31.35 | 2024 | Korlym |
| Kyowa Kirin, INC. | $27.68 | 2024 | Crysvita |
| Phathom Pharmaceuticals, INC. | $27.34 | 2024 | Voquezna |
| Eisai INC. | $20.66 | 2024 | |
| Dexcom, INC. | $17.79 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $15.86 | 2023 | Gvoke Hypopen |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.19 | 2024 | Trulance, Xifaxan |
| Mylan Specialty L.P. | $14.97 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Devries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.